These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3188916)

  • 21. Inhibition of dihydrofolate reductase: structure-activity correlations of 2,4-diamino-5-benzylpyrimidines based upon molecular shape analysis.
    Hopfinger AJ
    J Med Chem; 1981 Jul; 24(7):818-22. PubMed ID: 7277386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New antifolate 4,4'-diaminodiphenyl sulfone substituted 2,4-diamino-5-benzylpyrimidines. Proof of their dual mode of action and autosynergism.
    Wiese M; Schmalz D; Seydel JK
    Arch Pharm (Weinheim); 1996 Mar; 329(3):161-8. PubMed ID: 9005816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.
    Selassie CD; Fang ZX; Li RL; Hansch C; Klein T; Langridge R; Kaufman BT
    J Med Chem; 1986 May; 29(5):621-6. PubMed ID: 3701780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
    Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
    J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 11. Quinolylmethyl analogues with basic substituents conveying specificity.
    Davis SE; Rauckman BS; Chan JH; Roth B
    J Med Chem; 1989 Aug; 32(8):1936-42. PubMed ID: 2502633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.
    Selassie CD; Li RL; Poe M; Hansch C
    J Med Chem; 1991 Jan; 34(1):46-54. PubMed ID: 1899453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theory and application of molecular potential energy fields in molecular shape analysis: a quantitative structure--activity relationship study of 2,4-diamino-5-benzylpyrimidines as dihydrofolate reductase inhibitors.
    Hopfinger AJ
    J Med Chem; 1983 Jul; 26(7):990-6. PubMed ID: 6345782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
    Richardson ML; Croughton KA; Matthews CS; Stevens MF
    J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5793161
    [No Abstract]   [Full Text] [Related]  

  • 31. Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jul; 12(4):680-4. PubMed ID: 5822623
    [No Abstract]   [Full Text] [Related]  

  • 32. The antifolate activity of tea catechins.
    Navarro-Perán E; Cabezas-Herrera J; García-Cánovas F; Durrant MC; Thorneley RN; Rodríguez-López JN
    Cancer Res; 2005 Mar; 65(6):2059-64. PubMed ID: 15781612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystallography, quantitative structure-activity relationships, and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and Lactobacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s.
    Hansch C; Hathaway BA; Guo ZR; Selassie CD; Dietrich SW; Blaney JM; Langridge R; Volz KW; Kaufman BT
    J Med Chem; 1984 Feb; 27(2):129-43. PubMed ID: 6420569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Mavandadi F; Queener SF
    J Med Chem; 1997 Mar; 40(7):1173-7. PubMed ID: 9089339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of the inhibition of bovine liver dihydrofolate reductase by tea catechins: origin of slow-binding inhibition and pH studies.
    Navarro-Perán E; Cabezas-Herrera J; Hiner AN; Sadunishvili T; García-Cánovas F; Rodríguez-López JN
    Biochemistry; 2005 May; 44(20):7512-25. PubMed ID: 15895994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
    Gangjee A; Jain HD; Kisliuk RL
    Bioorg Med Chem Lett; 2005 May; 15(9):2225-30. PubMed ID: 15837298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.
    Selassie CD; Fang ZX; Li RL; Hansch C; Debnath G; Klein TE; Langridge R; Kaufman BT
    J Med Chem; 1989 Aug; 32(8):1895-905. PubMed ID: 2502631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of inhibition of wt-dihydrofolate reductase from E. coli by tea epigallocatechin-gallate.
    Spina M; Cuccioloni M; Mozzicafreddo M; Montecchia F; Pucciarelli S; Eleuteri AM; Fioretti E; Angeletti M
    Proteins; 2008 Jul; 72(1):240-51. PubMed ID: 18214969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the inhibitory action of 5-(substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver.
    Li R; Hansch C; Kaufman BT
    J Med Chem; 1982 Apr; 25(4):435-40. PubMed ID: 7069722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
    Gangjee A; Shi J; Queener SF
    J Med Chem; 1997 Jun; 40(12):1930-6. PubMed ID: 9191971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.